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Abstract
Metal-based drugs have undergone much development and application for therapeutic
and diagnostic purposes for many decades since the huge success of cisplatin and other
successful metal-drug complexes in the clinical stages. Furthermore, this metal-based
drug has come up with a lot of signs of resistance and side-effects in their uses. This re‐
view points to some of the resistance natures and mechanisms of previously synthesized
complexes in the field of chemistry.
Keywords: metal-drug complexes, antibacterial, mechanism, therapeutics, properties, re‐
sistance
1. Introduction
Anti-bacterial are agents that disturb and combat the growth and reproduction of bacteria.
They are known as agents used to disinfect surfaces and eliminate potentially harmful bacteria.
Some antibacterial agents are contraindicated while some required dosage modification in
patients who have renal insufficiency. The use of metal complexes as antibacterial/chemo‐
therapeutic agents against some ailments is a very attractive potential. Some metal complexes
including mixed ligand metal complexes have been prepared in our laboratory and that of
others. Their effectiveness as antibacterial agents has been revealed. Different synthetic
procedures were utilized.
Though development of metallo-pharmaceuticals is met with limitations because of the
perception that metals (especially when regarded as heavy metals) are toxic and the relative
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limited expertise of most pharmaceutical companies in Inorganic Chemistry, metals and their
compounds are essential to many species of plants and animals. Metal complexes may be
useful as research probes of biological function, as intermediary lead compounds in the
development of non-metal-containing therapeutics, and as potential diagnostic and therapeu‐
tic agents. The unique properties of metal complexes,(e. g., hydrolytic and redox activity,
valency, geometry, magnetic, spectroscopic, photo-physical, and radiochemical properties)
can be used to measure and/or alter cellular functions. In the recent past, polypyridyl metal
complexes are also being tested as chemotherapeutic agents following the first success of
cisplatin and the need to discover new drugs to combat the problem of resistance to existing
drugs [1-8].
The importance of metal in medicine has been in existence for many years and researchers
have explored their uses and advantages to human health, animals and the environment. Some
of these metals are content of our day-to-day diets and in varying quantities.
Many researchers have come up with the importance of metals in known drugs or synthesized
drugs. Transition metals are involved majorly in the formation of complexes by coordinating
with the ligands (i. e. the drugs).
Humans need several metal ions for many vital and important functions in the body in which
the lack of some of these metal ions can lead to malfunctioning of the body and development
of diseases. Iron deficiency can lead to pernicious anemia while copper deficiency in infants
can cause lack of accurate function of the heart.
Medicinal bioinorganic chemistry considers, from a molecular level point of view, how to
understand and recognize different diseases that originate from the deficiency of essential
metal ions functionality in the body of a living system. This also includes ways of providing
solution to these problems. Introduction of heavy metal ions (e. g., Pb and Hg) can be detri‐
mental to living systems [9].
The involvement of the metal ions in most of these potent synthesized complexes has increased
their biological activities. In most cases the acceleration of the action of many drugs is mainly
caused by metal ion chelation. Therefore many metals are involved in enhancing the efficacy
in antimalarial, antitumor and anticancer therapy [10-13].
Drug resistance refers to a situation in which the drugs that usually destroy the bacteria can
no longer perform its duty. It implies that the patient can no longer be effectively treated
against the bacteria.
Therefore, people become sick for a long time and if the epidemics are extended without a
possible solution it results in more people being at risk of becoming infected.
Antimicrobial resistance is the ability of a microorganism to survive at a given concentration
of anantimicrobial agent at which the normal population of the microorganism would be
killed.
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2. Resistance of some metal-drug complexes of antimalarial
2.1. Resistance to anti-malarials
Resistance to antimalarials could be defined as the tendency by which the parasite is able to
thrive and even reproduce itself in the presence of accurate dosage of malaria drug [14].
In  2006,  the  World  Health  Organisation  (WHO) stated  that,  resistance  has  arisen  to  all
classes  of  anti-malarials  except  the  artemisinins.  This  has  increased  the  malaria  burden
globally and is a most important threat to malaria control.  Extensive and indiscriminate
uses of antimalarial drugs impose a strong selective stress on Plasmodium falciparum  and
other malaria parasites to acquire higher resistance levels. This can be prevented at its onset
or mellowed down significantly, through combination therapies of the anti-malarial drugs
with differing modes  of  actions  thereby achieving maximum cure  rates  by strict  adher‐
ence to proper drug prescriptions [13].
The data acquired can be of assistance in treatment choices and forecasts concerning future
resistance patterns. The most difficult with drug resistance arises from P. falciparum. Resistance
due to P. falciparum is of special interest since the huge burden of disease arises from this class,
as well as its deadly potential, the tendency for epidemics, and the cost implication of replace‐
ment with candidate drugs in places with well-known drug resistance. Chloroquine resistance
does occur in P. vivax, particularly in Western Oceania. However, there is very scanty infor‐
mation on resistance in P. ovale and P. malariae [14].
Malaria is a deadly disease that affect both children and adult and is mostly caused by the
protozoan parasite Plasmodium, and is transmitted by an Anopheline mosquito vector [15]. The
five Plasmodia species affecting humans are Plasmodium falciparum, Plasmodium vivax,
Plasmodium ovale, Plasmodium malariae, and Plasmodium knowlesi. Plasmodium falciparum is a
common species commonly affecting the population and therefore its resistance to many
drugs. Today, the available therapeutic drugs for malaria are limited; new anti-malarial drugs,
preferably with new structures and/or modes of action, are urgently needed [16, 17].
The emergence of resistance in Plasmodium depends on parasite mutation rate and their total
parasite load. Treatment response and drug selection strength also contributed to these factors.
Increase in the rates of mutation enhances the speed of resistance emergence which subse‐
quently leads to harmful mutations [17].
3. Some metal-drug complexes resistance and their mechanism
3.1. Metal complexes of antimalarial drugs
Metal–drug synergism has been exploited to obtain effective antimalarial metal agents [18-20].
The use of chloroquine (CQ) as a major reference drug of all antimalarial drugs has enabled
many scientists to develop more potent drugs in combating malaria. Resistance against CQ is
Perception and Resistance Mechanism of some Metal-drug Complexes and Their Roles as Antibacterial
http://dx.doi.org/10.5772/61033
31
now prominent. The incorporation of metals into CQ and similar drugs has been yielding more
positive results with little or no toxicity. Some examples of synthesized metal- drug complexes
including their various resistances are also cited in the table below:
For Ruthenium and Rhodium complexes of chloroquine:
 
 
 
Ru-chloroquine 
(A) (B) 
Rh-chloroquine 
[RuCQCl2]2 RhCl(COD)CQ 
Compound CQ-Sensitive strains CQ-Resistance strains Reference
A P. berghei FcB1, FcB2 [21]
B Reduction of parasitemia by 73% FcB1 [21]
Where (COD: 1,5-Cyclooctadiene), Ru- Ruthenium, Rh= Rhenium,
 
 
 
 
1. R = CH3, X= PF6 (Au-CQ) 
2. R = C6H5, X = PF6  
3. R = C6H5, X = NO3 
4. R = C2H5, X = PF6 
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Compound CQ-Sensitive strains of P.
berghei
CQ-Resistance strains of P.
falciparum
Reference
1. [Au(PMe3)(CQ)]PF6] F32 W2, K1, FcB1 [23]
2. [Au(PPh3)(CQ)]PF6 F32 FcB1, FcB2 [22]
3. [Au(PPh3)(CQ)]NO3 F32 W2, K1, FcB1 [23]
4. [Au(PEt3)(CQ)]PF6 F32 W2, K1, FcB1 [22]
From the conclusion that was drawn from the mechanism of [Au(PPh3)(CQ)]PF6 and its
antimalarial action, [Au(PPh3)(CQ)]PF6 has high propensity to haem than chloroquine
diphosphate. The same complex also shows high ability to inhibit β-haematin formation.
The mechanism of antimalarial action of [Au(CQ)(PPh3)]PF6 has been clearly defined [22].
Structural effects and increased drug lipophilicity enhance haem aggregation inhibition at
lipid/water interfaces [24].
 
1. R1 = -CH3, R2 = -CH(CH3)2, X = Cl- 
2. R1=R2 = H, X = Cl- 
Compound CQ-Sensitive strains CQ-Resistance strains Reference
6 FcB1, 3D7, PFB, F32 W2, Dd2, K1 [25]
7 FcB1, 3D7, PFB, F32 W2, Dd2, K1 [25]
The description of CQ derivatives with Arene−metal complexes and half-sandwich complexes
are shown above, where some of them showed high antiplamodial activity and some showed
different modes of binding with CQ.
Ferroquine (FQ) shows higher biological and structural activity than any other antimalarial
drugs in the market including chloroquine (CQ). The reaction of FQ and CQ against P.
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falciparum strains is quite unique and different in which FQ reveal some high potency in
chloroquine-resistant and chloroquine-sensitive P. falciparum strains[26-32].
Indeed it has been observed that a number of drugs that are active against CQ-resistant strains,
including metal-based CQ derivatives, such as the iron-containing ferroquine [21,28,33] and
the gold-CQ complex [Au(CQ)(PPh3)]PF6 [34], are considerably more lipophilic than CQ and
this could be an important factor in the reduction of resistance.
Antiplasmodial activity of the synthetic products of chloroquine-bridged ferrocenophane
analogues of ferroquine were reported by Salas et. al. (2013) [35]. All the disubstituted bridged
ferrocenyl compounds were observed to be active against all the tested parasite strains.
The activities of some of the compounds under investigation were observed to be sensitive to
the drug resistance level of the parasite strains. It was noted that:
• FQ was twenty times or more potent or operative against chloroquine-resistant parasite
strains than CQ;
• FQ also displayed high level of potency in vivo in some experiments against P. berghei, P.
vinckei and P. yoeli;
• Due to the different formulation and structure, there were no expected differences.
 
ferrocene−pyrrolo[1,2-α]quinoxaline compounds 
This drug has shown lower resistance than chloroquine, therefore making their derivatives a
good contender for chloroquine-resistant malaria. [36]. The most potent of this derivative
contains a methoxy group just like the above.
Compound CQ-Sensitive strains CQ-Resistance strains Reference
F F32 FcB1, PFB [36]
 Ferroquine 
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4. Multiple drug resistance mechanisms in cancer
The process and system whereby resistance to one drug is accompanied by resistance to drugs
whose structures and mechanisms of action may be completely different is called multiple
drug resistance (MDR). [37-42]
4.1. Platinum anticancer agents
One of the most effectively used drugs in cancer and for its treatment is the family called
Platinium (II) complexes. The following compounds have been clinically approved for
treatment universally.
Carboplatin 
                                              
Cisplatin Oxaliplatin 
Consideration of the toxic reduction of platinum complexes in living cells has been of special
interest over the years. This happened so as to have a wider range of cure over other types of
cancer that have come to light, hereby avoiding being stopped by some resistance. [43-45]
The usefulness of Platinum complexes in the clinical stage is limited by:
i. the spectrum of its anticancer activity (not active enough against several types of
cancer),
ii. the development of resistance after continued treatment, and
iii. its high toxicity to some normal cells.
 
Pt
OCOCH3
OCOCH3
Cl
Cl
H3N
HN
                          
 
Oxaliplatin 
JM216 
AMD473 
Some of the current thinking on the chemical basis for the mechanism of action of cisplatin as
an anticancer drug is summarized below:
In 2000, Pe´rez et. al. [46], were able to report the first crystal structure of a biologically active
trans-platinum compound trans-[PtCl2(dimethylamine)(isopropylamine) containing different
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aliphatic amines where trans-PtCl2(dimethylamine)-(isopropylamine)] readily form DNA
inter-stand crosslinks.
                                            
                                                   Trans-[PtCl2(dimethylamine)(isopropylamine)]            
 
 
traCC)(Cisopropy Transplatin lamincce) Transplatin 
But in the year 2003, Ramos-Lima et al, were able to replace two amine groups of transplatin
with aliphatic amine and phosphane group, which resulted in circumvention of cisplatin
resistance [47-48].
The synthesis pathway for the novel complexes is shown below;
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Resistance 
× 
Resistance 
Reduce Pt Uptake 
Pt drug Active Pt 
Complex 
GSH M T 
Inactivation 
Resistance 
Pt-SG 
e.g. hydrolysis 
Pt 
DNA Adduct 
Pt 
Repair 
Excision 
Apotosis cell 
death 
Not Repair 
Shield from 
repair (HMG) 
Resistance 
Activation 
Figure 1. A summary of some of the processes that are thought to be involved in the cytotoxicity of platinum anticanc‐
er agents
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In 2014, Obaleye and co-workers synthesized and characterized a novel –M–X–M–X– type
infinite chain 1D Cu(II) complex with eflornithine hydrochloride hydrate as ligand where their
biological evaluation were examined and the results of the antibacterial screening show
appreciable activity of the metal-drug complexes compared to the ligand when challenged
with test organisms at varying concentrations. Copper complex was effective at virtually all
concentrations used except against E. coli and P. aeruginosa at 0. 0001 gL-1 [49].
Highest susceptibility to Copper complex was recorded by S. aureus with clearance zone of 4.
2 mm at 1. 0 gL-1. The results show that the metal-drug complex possesses a measure of
antibacterial activity against all the organisms tested. The results also agree with the findings
of other researchers [50-51] that antibacterial potency is usually concentration dependent.
The data also revealed that the activity of the Ligand EFL was bacteriostatic against all the
organisms tested, while the activity of the copper (II) complex was bacteriostatic against E.
coli and P. aeruginosa but bactericidal against S. aureus at 0. 0001 g/L concentration.
The Scheme of the reaction is shown below:
Eflornithine Hydrochloride Hydrate 
Ligand EFL 
5. Conclusion
For a couple of years now, some bacteria are becoming resistant to antibiotic drugs during this
era of chemotherapy. This has been the main cause of morbidity and mortality worldwide.
Many reasons had been attached to this drug resistance of the organism. Some of these
proposed reasons are (i) the over-prescription of the drugs by physicians,(ii) self-medication,
(iii) premature discontinuity of the medication by the patients as they start to regain strength
and (iv) difficulty in affording the full course of the therapy. Other factors such as the trans‐
mission of the drug-resistant organism among patients through air or by direct contact with
contaminated person or environment have been identified. It is also attested that a long period
is usually needed to complete the treatment of individuals infected by the organisms. Modes
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of action of some of the potent antibiotic drugs are sometimes tagged as unknown. Hence,
there is urgent need for continuous research in the development of drugs in order to have more
effective drugs than the already available less potent drugs that will combat these dangerous
microbes.
Although several metal-drug complexes have been synthesized to date, there are few of them
at the final clinical stage due to their resistance capacity. Many researches are ongoing to
circumvent this drug resistance, from this review, it is clear that some of the existing organic
ligands or their derivatives are observed to be more potent when complexed with metals. These
metal-drug complexes are in vitro and in vivo efficient.
In the aspect of antimalarial, antitumor, and anticancer drugs, more profitable researches are
gradually emerging, yielding positive products with decent potency, stability, and reduced
side effects. In this review resistance mechanisms of some synthesized metal-drug complexes
were highlighted based on the investigations of various researchers.
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